Register below for the METAvivor/MRS Metastatic Cancer Stakeholder Engagement Conference on June 7 and 8, 2019 at the Lineberger Cancer Center at the University of North Carolina, Chapel Hill. Once registered, click here to book your room at the Courtyard by Marriott Chapel Hill.
A limited number of patient travel grants are available. Please contact email@example.com for an application.
Friday, June 7, 2019 - Conference Check-In 7:30 am - 8:15 am
Conference: 8:15 - 4:00 pm - Lunch and Breaks Included
Saturday, June 8, 2019 - Conference Check-In 8:00 am - 8:30 am
Conference: 8:30 am - 3:00 pm - Lunch and Breaks Included
PCORI Conference Room Block
Courtyard Chapel Hill for $129 USD per night
Room Block Start Date: Thursday, June 6, 2019 - Room Block End Date: Saturday, June 8, 2019
Last Day to Book: Monday, May 6, 2019
Despite decades of cancer research, cancer metastasis (the spread of cancer from the primary site throughout the body) still causes approximately 90% of all cancer-related deaths worldwide and in the U.S. specifically (American Cancer Society and World Health Organization). There is no cure for metastatic cancer of any type.
Translational metastasis researchers and clinicians of the Metastasis Research Society have partnered with patient advocates of METAvivor Research and Support Inc. and clinicians from the Sentinel Node Oncology Foundation to create a one-of-a-kind conference and webinar series meant to engage researchers, clinicians, and patients together in metastasis research to improve stage IV metastatic cancer patient outcomes and quality of life. Year 1 of the project focused on metastatic breast cancer specifically (2017-2018) and year 2 has been expanded to continue focus on metastatic breast cancer but also include all metastatic cancer types (2018-2019). More information on year 2 can be found here.
1. Engage and educate stakeholders (patients, clinicians, researchers) in translational metastasis research and clinical comparative effectiveness research (CER). CER compares the benefits and harms of different treatment options or interventions that are already available to improve patient outcomes and quality of life relatively quickly. 2. Set research priorities for translational metastatic breast cancer research (a path forward for new treatments). 3. Set priorities for metastatic breast cancer clinical comparative effectiveness research (CER - a path forward for existing therapies) 4. Develop a sustainable model for patient engagement in metastasis research to engage key stakeholders in cancer metastasis to strengthen and advance patient-centered metastasis research from basic translational research through clinical comparative effectiveness research (CER). CER compares the use of existing therapies to improve patient outcomes relatively quickly.
Project collaborators include: translational metastasis researchers and clinicians of the Metastasis Research Society (MRS), patients/patient advocates of METAvivor Research and Support Inc. (project lead), and clinicians of the Sentinel Node Oncology Foundation (SNOF, project partner).